M. abscessus (MA) is an emerging multidrug resistance (MDR) non-tuberculous mycobacteria (NTM) that affects cystic fibrosis (CF) patients and is often associated with the decline in lung function. Liposomes carrying bioactive lipids have been recently demonstrated, at preclinical level, to be able to enhance bactericidal innate immunity, against multidrug resistant (MDR) pulmonary infections. The main goal of the project will be to assess the therapeutic effect of different liposome formulations on MA pulmonary disease progression. The murine model of long term chronic MA lung infection, recently established in the laboratory, will be useful to identify the best liposome formulations able to reduce MA chronic infection and to evaluate the synergistic effect of the selected liposome with an antibiotic treatment. The expectation is to identify a new therapeutic strategy based on liposomes effective in strengthening the natural immune response against MA infection. Since MA becomes chronic in cystic fibrosis because of the fact that macrophages are not capable of removing it, another goal of the project is to improve the activity of macrophages carrying FC mutation. Liposomes delivering bioactive lipid could represent a novel immunotherapeutic strategy to treat pulmonary infection by drug-resistant MA in CF patients.